MESOBLAST LIMITED - Announcements

Market Cap $1.238B Add to my watchlist

Healthcare Biotechnology

Mesoblast Limited is an Australia-based is developing a range of late-stage product... Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) is stepping up its trial activities in Australia’s nearest Asian neighbour, Indonesia. Recce’s flagship anti-infective, R327, can be applied as a gel – and this gel-based version of the drug has been of specific interest...

Announcements

Filter Results

All Price Sensitive Only

MSB	Third Quarter Results Presentation		31/05/19	3.41MB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	31/05/19	536.5KB	Share
MSB	MSB Financial Results Webcast Timing		30/05/19	70.43KB	Share
MSB	Mesoblast Initiates Rolling Submission of BLA for GvHD	PRICE SENSITIVE	30/05/19	94.56KB	Share
MSB	Mesoblast Keynote Presentations at ISCT Annual Meeting		23/05/19	250.96KB	Share
MSB	Mesoblast to Present at RBC Global Healthcare Conference		17/05/19	65KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/19	134.84KB	Share
MSB	FDA Agrees to Rolling Review of Mesoblast BLA Submission		16/04/19	121.86KB	Share
MSB	Final Director's Interest Notice		05/04/19	60.47KB	Share
MSB	Presentation at Upcoming Global Life Science Conference		05/04/19	80.76KB	Share
MSB	MoU for Confirmatory Trial for GI Bleeding in LVAD Patients	PRICE SENSITIVE	27/03/19	107.1KB	Share
MSB	MSB Licensee Files For Skin Disease Marketing Approval	PRICE SENSITIVE	25/03/19	91.43KB	Share
MSB	Joseph R. Swedish Appointed Mesoblast Chairman		22/03/19	89.81KB	Share
MSB	Change in substantial holding		18/03/19	187.71KB	Share
MSB	Upcoming U.S. Investor Conferences		13/03/19	96.33KB	Share
MSB	Mesoblast Provides Half Year Results and Corporate Update	PRICE SENSITIVE	21/02/19	187.06KB	Share
MSB	Half Year Financial Results Presentation		21/02/19	1.35MB	Share
MSB	Half Year Report and Accounts (including Appendix 4D)	PRICE SENSITIVE	21/02/19	693.79KB	Share
MSB	Final Patient Dosed in Mesoblast P3 Heart Failure Trial		19/02/19	87.78KB	Share
MSB	Mesoblast Newsletter on Advanced and End-Stage Heart Failure		19/02/19	237.48KB	Share
MSB	Change in substantial holding		11/02/19	188.74KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19	133.52KB	Share
MSB	MSB Draws US$15 Million From Existing Facility	PRICE SENSITIVE	14/01/19	122.84KB	Share
MSB	MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase		08/01/19	213.69KB	Share
MSB	Change of Director's Interest Notices		08/01/19	183.24KB	Share
MSB	P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment	PRICE SENSITIVE	07/01/19	88.48KB	Share
MSB	Cleansing notice and Appendix 3B		07/01/19	264.09KB	Share
MSB	Mesoblast Corporate Review		28/12/18	135.21KB	Share
MSB	Mesoblast to Present at 2019 Biotech Showcase in USA		24/12/18	71.28KB	Share
MSB	MSB Makes Executive Appointment To Drive Commercialization		19/12/18	103.05KB	Share
MSB	Meetings Held With FDA Support MSB's Planned GVHD Filing		13/12/18	90.54KB	Share
MSB	Response to ASX query	PRICE SENSITIVE	05/12/18	421.44KB	Share
MSB	Results of Meeting		30/11/18	177.79KB	Share
MSB	Presentation to 2018 Annual General Meeting		30/11/18	1.37MB	Share
MSB	Chairman's Address to Shareholders		30/11/18	75.97KB	Share
MSB	Tasly and MSB Initiate Activities For MPC-150-IM In China		26/11/18	344.04KB	Share
MSB	MSB Provides Q1 Financial Results and Operational Highlights	PRICE SENSITIVE	16/11/18	304.15KB	Share
MSB	First Quarter Results Presentation		16/11/18	2.76MB	Share
MSB	First Quarter Financial Results on Form 6-K	PRICE SENSITIVE	16/11/18	468.25KB	Share
MSB	LVAD Results Webcast Presentation	PRICE SENSITIVE	13/11/18	1.58MB	Share
MSB	LVAD Trial Results Provide Potential Regulatory Pathway	PRICE SENSITIVE	12/11/18	153.14KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	12/11/18	115.8KB	Share
MSB	MSB To Host Webcast For Heart Failure Results At AHA		09/11/18	67.84KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/18	124.88KB	Share
MSB	Annual Report to shareholders		30/10/18	2.41MB	Share
MSB	Notice of General Meeting/Proxy Form		30/10/18	302.32KB	Share
MSB	Appendix 4G and Corporate Governance Statement		30/10/18	183.17KB	Share
MSB	GVHD and CHF Updates to Emerging Leaders Conference		25/10/18	2.48MB	Share
MSB	MSB Expands Partnership With JCR For Skin Disease	PRICE SENSITIVE	24/10/18	92.16KB	Share
MSB	Change in substantial holding		16/10/18	260.5KB	Share
MSB	Completion of Tasly Transaction, and Appendix 3B	PRICE SENSITIVE	12/10/18	302.01KB	Share
MSB	Release of shares from voluntary escrow		11/10/18	85.28KB	Share
MSB	End-Stage HF Results Selected For AHA Scientific Sessions		02/10/18	87.78KB	Share
MSB	Mesoblast Cardiac Cell Therapy In Children		25/09/18	95.15KB	Share
MSB	Day 180 Survival Outcomes In aGvHD Phase 3 Trial	PRICE SENSITIVE	20/09/18	97.85KB	Share
MSB	Tasly Receives Approvals For Transaction With MSB	PRICE SENSITIVE	17/09/18	71.22KB	Share
MSB	Mesoblast Reports on Annual and Fourth Quarter Results	PRICE SENSITIVE	30/08/18	219.59KB	Share
MSB	Annual Financial Results Presentation		30/08/18	2.21MB	Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	30/08/18	1.6MB	Share
MSB	UPDATE ON TASLY TRANSACTION	PRICE SENSITIVE	29/08/18	89.39KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/18	117.52KB	Share
MSB	Initial Director's Interest Notice		18/07/18	62.49KB	Share
MSB	MSB Enters Into Cardiovascular Alliance For China With Tasly	PRICE SENSITIVE	17/07/18	80.49KB	Share
MSB	Director Appointment/Resignation		11/07/18	89.85KB	Share
MSB	Appendix 3B		10/07/18	184.33KB	Share
MSB	MSB Enters Into US$50M Financing With NovaQuest Capital	PRICE SENSITIVE	02/07/18	80.37KB	Share
MSB	Initial and Final Directors' Interest Notices		25/06/18	140.45KB	Share
MSB	ISSCR Presentation on P3 GVHD Trial Survival Benefits		22/06/18	1.77MB	Share
MSB	Key Day 100 Survival Results In P3 GvHD Trial	PRICE SENSITIVE	21/06/18	76.22KB	Share
MSB	Director Appointment/Resignation		19/06/18	74.62KB	Share
MSB	MSB Provides Q3 Financial Results and Operational Highlights		31/05/18	212.11KB	Share
MSB	Mesoblast Appoints New Chief Financial Officer		31/05/18	74.97KB	Share
MSB	Third Quarter Results Presentation		31/05/18	965.73KB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	31/05/18	515.82KB	Share
MSB	Partnership For Allogeneic Cell-based Cancer Immunotherapies	PRICE SENSITIVE	29/05/18	77.36KB	Share
MSB	Cleansing notice and Appendix 3B		15/05/18	233.86KB	Share
MSB	MSB P3 Results For GVHD Presented At ISCT Meeting		08/05/18	95.17KB	Share
MSB	MSB Cell Therapies Featured At Vatican Healthcare Conference		01/05/18	73KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/18	114.44KB	Share
MSB	MSB Clinical Program Update For MPC-150-IM In Heart Failure		18/04/18	106.86KB	Share
MSB	Mesoblast Phase 3 CLBP Trial Completes Enrollment		29/03/18	99.5KB	Share
MSB	Change in substantial holding		09/03/18	187.57KB	Share
MSB	MSB Enters Into $75 Million Non-Dilutive Credit Facility	PRICE SENSITIVE	07/03/18	91.99KB	Share
MSB	Mesoblast Provides Half Year Results and Corporate Update		28/02/18	237.2KB	Share
MSB	Half Year Results Presentation		28/02/18	3.21MB	Share
MSB	Half Year Report and Accounts (including Appendix 4D)	PRICE SENSITIVE	28/02/18	558.51KB	Share
MSB	GVHD Day 28 Results Presentation	PRICE SENSITIVE	23/02/18	1.85MB	Share
MSB	Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial	PRICE SENSITIVE	22/02/18	103.81KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/18	96.37KB	Share
MSB	Appendix 3B with prospectus	PRICE SENSITIVE	19/01/18	481.29KB	Share
MSB	Presentation to J.P. Morgan 2018 Healthcare Conference		12/01/18	3.6MB	Share
MSB	Presentation at JP Morgan Healthcare Conference		11/01/18	69.98KB	Share
MSB	Change of Director's Interest Notice		22/12/17	88.88KB	Share
MSB	Mesoblast Receives RMAT For LVAD Heart Failure Patients	PRICE SENSITIVE	21/12/17	86.83KB	Share
MSB	Release of shares from voluntary escrow		20/12/17	83.61KB	Share
MSB	Mesoblast's P3 GVHD Trial Completes Enrollment	PRICE SENSITIVE	20/12/17	93.71KB	Share
MSB	Mesoblast Grants TiGenix License For Treatment of Fistulae	PRICE SENSITIVE	15/12/17	73.63KB	Share
MSB	MSB Named Global Technology Leader In Cell Therapy Industry	PRICE SENSITIVE	08/12/17	90.71KB	Share
MSB	Change in substantial holding		07/12/17	280.18KB	Share
MSB	Change in substantial holding		05/12/17	291.65KB	Share

MSB Third Quarter Results Presentation
31/05/19		3.41MB	Share
MSB Third Quarter Financial Results on Form 6-K
31/05/19	PRICE SENSITIVE	536.5KB	Share
MSB MSB Financial Results Webcast Timing
30/05/19		70.43KB	Share
MSB Mesoblast Initiates Rolling Submission of BLA for GvHD
30/05/19	PRICE SENSITIVE	94.56KB	Share
MSB Mesoblast Keynote Presentations at ISCT Annual Meeting
23/05/19		250.96KB	Share
MSB Mesoblast to Present at RBC Global Healthcare Conference
17/05/19		65KB	Share
MSB Appendix 4C - quarterly
30/04/19	PRICE SENSITIVE	134.84KB	Share
MSB FDA Agrees to Rolling Review of Mesoblast BLA Submission
16/04/19		121.86KB	Share
MSB Final Director's Interest Notice
05/04/19		60.47KB	Share
MSB Presentation at Upcoming Global Life Science Conference
05/04/19		80.76KB	Share
MSB MoU for Confirmatory Trial for GI Bleeding in LVAD Patients
27/03/19	PRICE SENSITIVE	107.1KB	Share
MSB MSB Licensee Files For Skin Disease Marketing Approval
25/03/19	PRICE SENSITIVE	91.43KB	Share
MSB Joseph R. Swedish Appointed Mesoblast Chairman
22/03/19		89.81KB	Share
MSB Change in substantial holding
18/03/19		187.71KB	Share
MSB Upcoming U.S. Investor Conferences
13/03/19		96.33KB	Share
MSB Mesoblast Provides Half Year Results and Corporate Update
21/02/19	PRICE SENSITIVE	187.06KB	Share
MSB Half Year Financial Results Presentation
21/02/19		1.35MB	Share
MSB Half Year Report and Accounts (including Appendix 4D)
21/02/19	PRICE SENSITIVE	693.79KB	Share
MSB Final Patient Dosed in Mesoblast P3 Heart Failure Trial
19/02/19		87.78KB	Share
MSB Mesoblast Newsletter on Advanced and End-Stage Heart Failure
19/02/19		237.48KB	Share
MSB Change in substantial holding
11/02/19		188.74KB	Share
MSB Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE	133.52KB	Share
MSB MSB Draws US$15 Million From Existing Facility
14/01/19	PRICE SENSITIVE	122.84KB	Share
MSB MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase
08/01/19		213.69KB	Share
MSB Change of Director's Interest Notices
08/01/19		183.24KB	Share
MSB P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment
07/01/19	PRICE SENSITIVE	88.48KB	Share
MSB Cleansing notice and Appendix 3B
07/01/19		264.09KB	Share
MSB Mesoblast Corporate Review
28/12/18		135.21KB	Share
MSB Mesoblast to Present at 2019 Biotech Showcase in USA
24/12/18		71.28KB	Share
MSB MSB Makes Executive Appointment To Drive Commercialization
19/12/18		103.05KB	Share
MSB Meetings Held With FDA Support MSB's Planned GVHD Filing
13/12/18		90.54KB	Share
MSB Response to ASX query
05/12/18	PRICE SENSITIVE	421.44KB	Share
MSB Results of Meeting
30/11/18		177.79KB	Share
MSB Presentation to 2018 Annual General Meeting
30/11/18		1.37MB	Share
MSB Chairman's Address to Shareholders
30/11/18		75.97KB	Share
MSB Tasly and MSB Initiate Activities For MPC-150-IM In China
26/11/18		344.04KB	Share
MSB MSB Provides Q1 Financial Results and Operational Highlights
16/11/18	PRICE SENSITIVE	304.15KB	Share
MSB First Quarter Results Presentation
16/11/18		2.76MB	Share
MSB First Quarter Financial Results on Form 6-K
16/11/18	PRICE SENSITIVE	468.25KB	Share
MSB LVAD Results Webcast Presentation
13/11/18	PRICE SENSITIVE	1.58MB	Share
MSB LVAD Trial Results Provide Potential Regulatory Pathway
12/11/18	PRICE SENSITIVE	153.14KB	Share
MSB Pause in Trading
12/11/18	PRICE SENSITIVE	115.8KB	Share
MSB MSB To Host Webcast For Heart Failure Results At AHA
09/11/18		67.84KB	Share
MSB Appendix 4C - quarterly
31/10/18	PRICE SENSITIVE	124.88KB	Share
MSB Annual Report to shareholders
30/10/18		2.41MB	Share
MSB Notice of General Meeting/Proxy Form
30/10/18		302.32KB	Share
MSB Appendix 4G and Corporate Governance Statement
30/10/18		183.17KB	Share
MSB GVHD and CHF Updates to Emerging Leaders Conference
25/10/18		2.48MB	Share
MSB MSB Expands Partnership With JCR For Skin Disease
24/10/18	PRICE SENSITIVE	92.16KB	Share
MSB Change in substantial holding
16/10/18		260.5KB	Share
MSB Completion of Tasly Transaction, and Appendix 3B
12/10/18	PRICE SENSITIVE	302.01KB	Share
MSB Release of shares from voluntary escrow
11/10/18		85.28KB	Share
MSB End-Stage HF Results Selected For AHA Scientific Sessions
02/10/18		87.78KB	Share
MSB Mesoblast Cardiac Cell Therapy In Children
25/09/18		95.15KB	Share
MSB Day 180 Survival Outcomes In aGvHD Phase 3 Trial
20/09/18	PRICE SENSITIVE	97.85KB	Share
MSB Tasly Receives Approvals For Transaction With MSB
17/09/18	PRICE SENSITIVE	71.22KB	Share
MSB Mesoblast Reports on Annual and Fourth Quarter Results
30/08/18	PRICE SENSITIVE	219.59KB	Share
MSB Annual Financial Results Presentation
30/08/18		2.21MB	Share
MSB Preliminary Final Report including Appendix 4E
30/08/18	PRICE SENSITIVE	1.6MB	Share
MSB UPDATE ON TASLY TRANSACTION
29/08/18	PRICE SENSITIVE	89.39KB	Share
MSB Appendix 4C - quarterly
31/07/18	PRICE SENSITIVE	117.52KB	Share
MSB Initial Director's Interest Notice
18/07/18		62.49KB	Share
MSB MSB Enters Into Cardiovascular Alliance For China With Tasly
17/07/18	PRICE SENSITIVE	80.49KB	Share
MSB Director Appointment/Resignation
11/07/18		89.85KB	Share
MSB Appendix 3B
10/07/18		184.33KB	Share
MSB MSB Enters Into US$50M Financing With NovaQuest Capital
02/07/18	PRICE SENSITIVE	80.37KB	Share
MSB Initial and Final Directors' Interest Notices
25/06/18		140.45KB	Share
MSB ISSCR Presentation on P3 GVHD Trial Survival Benefits
22/06/18		1.77MB	Share
MSB Key Day 100 Survival Results In P3 GvHD Trial
21/06/18	PRICE SENSITIVE	76.22KB	Share
MSB Director Appointment/Resignation
19/06/18		74.62KB	Share
MSB MSB Provides Q3 Financial Results and Operational Highlights
31/05/18		212.11KB	Share
MSB Mesoblast Appoints New Chief Financial Officer
31/05/18		74.97KB	Share
MSB Third Quarter Results Presentation
31/05/18		965.73KB	Share
MSB Third Quarter Financial Results on Form 6-K
31/05/18	PRICE SENSITIVE	515.82KB	Share
MSB Partnership For Allogeneic Cell-based Cancer Immunotherapies
29/05/18	PRICE SENSITIVE	77.36KB	Share
MSB Cleansing notice and Appendix 3B
15/05/18		233.86KB	Share
MSB MSB P3 Results For GVHD Presented At ISCT Meeting
08/05/18		95.17KB	Share
MSB MSB Cell Therapies Featured At Vatican Healthcare Conference
01/05/18		73KB	Share
MSB Appendix 4C - quarterly
30/04/18	PRICE SENSITIVE	114.44KB	Share
MSB MSB Clinical Program Update For MPC-150-IM In Heart Failure
18/04/18		106.86KB	Share
MSB Mesoblast Phase 3 CLBP Trial Completes Enrollment
29/03/18		99.5KB	Share
MSB Change in substantial holding
09/03/18		187.57KB	Share
MSB MSB Enters Into $75 Million Non-Dilutive Credit Facility
07/03/18	PRICE SENSITIVE	91.99KB	Share
MSB Mesoblast Provides Half Year Results and Corporate Update
28/02/18		237.2KB	Share
MSB Half Year Results Presentation
28/02/18		3.21MB	Share
MSB Half Year Report and Accounts (including Appendix 4D)
28/02/18	PRICE SENSITIVE	558.51KB	Share
MSB GVHD Day 28 Results Presentation
23/02/18	PRICE SENSITIVE	1.85MB	Share
MSB Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
22/02/18	PRICE SENSITIVE	103.81KB	Share
MSB Appendix 4C - quarterly
31/01/18	PRICE SENSITIVE	96.37KB	Share
MSB Appendix 3B with prospectus
19/01/18	PRICE SENSITIVE	481.29KB	Share
MSB Presentation to J.P. Morgan 2018 Healthcare Conference
12/01/18		3.6MB	Share
MSB Presentation at JP Morgan Healthcare Conference
11/01/18		69.98KB	Share
MSB Change of Director's Interest Notice
22/12/17		88.88KB	Share
MSB Mesoblast Receives RMAT For LVAD Heart Failure Patients
21/12/17	PRICE SENSITIVE	86.83KB	Share
MSB Release of shares from voluntary escrow
20/12/17		83.61KB	Share
MSB Mesoblast's P3 GVHD Trial Completes Enrollment
20/12/17	PRICE SENSITIVE	93.71KB	Share
MSB Mesoblast Grants TiGenix License For Treatment of Fistulae
15/12/17	PRICE SENSITIVE	73.63KB	Share
MSB MSB Named Global Technology Leader In Cell Therapy Industry
08/12/17	PRICE SENSITIVE	90.71KB	Share
MSB Change in substantial holding
07/12/17		280.18KB	Share
MSB Change in substantial holding
05/12/17		291.65KB	Share

REFRESH

First 3 4 5 6 7

(20min delay)
Last $1.09		Change 0.015(1.40%)		Mkt cap ! $1.238B

Open	High	Low	Value	Volume
$1.11	$1.12	$1.08	$11.51M	10.52M

Buyers (Bids)

No.	Vol.	Price($)
2	17804	$1.09

Sellers (Offers)

Price($)	Vol.	No.
$1.09	230637	5

View Market Depth

No.	Vol.	Price($)
1	2500	1.085
8	103868	1.080
4	20400	1.075
11	85089	1.070
4	50577	1.065

Price($)	Vol.	No.
1.090	5437	2
1.095	19582	2
1.100	34717	4
1.105	10000	1
1.110	53313	3

Last trade - 16.10pm 03/05/2024 (20 minute delay)


Last $1.09		Change 0.015 ( 1.85 %)
Open	High	Low	Volume
$1.10	$1.12	$1.08	1937390
Last updated 15.59pm 03/05/2024 ?

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories